Detection systems and methods for predicting the dissolution curve of a drug from a pharmaceutical dosage form

• US 6,558,957 B1
• Filed: 11/07/2000
• Issued: 05/06/2003
• Est. Priority Date: 06/04/1996
• Status: Expired due to Term

• Current Assignee: Pion Acquistion, Inc.
• Original Assignee: Delphi Technologies Incorporated M/C 480-410-202
• Inventors: Palermo, Philip J., Cheng, Frank S., Roinestad, Kurt, Bynum, Kevin
• Primary Examiner(s): LUDLOW, JAN M
• Application Number:
  US09/707,498
• Time in Patent Office: 910 Days
• Field of Search: 422/82.01, 422/82.05, 422/82.09, 422/82.11, 436/151, 436/164, 436/173, 436/181, 738/66, 738/665
• US Class Current: 436/164
• CPC Class Codes: G01N 13/00 Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects scanning-probe techniques or apparatus G01Q
• CPC Class Codes: G01N 2013/006 Dissolution of tablets or the like
• CPC Class Codes: G01N 2021/6484 Optical fibres
• CPC Class Codes: G01N 2021/651 Cuvettes therefore
• CPC Class Codes: G01N 2021/8521 with a combination mirror cell-cuvette
• CPC Class Codes: G01N 2021/8528 Immerged light conductor
• CPC Class Codes: G01N 21/01 Arrangements or apparatus for facilitating the optical investigation
• CPC Class Codes: G01N 21/05 Flow-through cuvettes G01N21/09 takes precedence; handling fluid samples G01N1/10
• CPC Class Codes: G01N 21/33 using ultraviolet light G01N21/39 takes precedence
• CPC Class Codes: G01N 21/359 using near infrared light
• CPC Class Codes: G01N 21/65 Raman scattering
• CPC Class Codes: G01N 21/8507 Probe photometers, i.e. with optical measuring part dipped into fluid sample
• CPC Class Codes: G01N 33/15 Medicinal preparations ; Physical properties thereof, e.g. dissolubility drug screening with animal cells G01N33/5008
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
• CPC Class Codes: Y10T 436/25875 Gaseous sample or with change of physical state

Abstract

The present invention relates to an improvement in a detection system used for continuously measuring the release of a drug from a pharmaceutical dosage form comprising a singular dissolution vessel or multiple dissolution vessels containing a dissolution medium and a measuring device for detecting the amount of drug released at a given time, the improvement comprising a mixing shaft and a probe placed within the mixing shaft or outside the individual dissolution vessels, the probe capable of measuring the dissolution characteristics using UV, IR, near-IR, fluorescence, electrochemical, and Raman spectroscopy techniques. The present invention also relates to a method for predicting the dissolution curve provided by a controlled release pharmaceutical dosage form comprising taking continuous measurements of the amount of drug released from a dosage form for a portion of the time over which the drug is expected to be released and predicting the remainder of the dissolution curve based on the values obtained.

Claims

1. An apparatus for determining a dissolution profile of a pharmaceutical dosage form containing a releasable quantity of a therapeutically active agent wherein the dosage form is immersed in a dissolution medium contained in a vessel, comprising:

a vessel for immersing a pharmaceutical dosage form in a dissolution medium;

a fiber optic probe disposed within the vessel and immersed in the dissolution medium;

a processor coupled to the fiber optic probe, the processor continuously receiving information from the fiber optic probe as the dissolution of the dosage form in the dissolution medium proceeds, the processor analyzing the information and continuously generating a dissolution profile of the dosage form as the dissolution of the dosage form in the dissolution medium proceeds.

2. The apparatus of claim 1, wherein the processor includes a computer and a UV-spectrometer.

3. The apparatus of claim 1, further comprising a rotatable mixing shaft disposed within the vessel.

4. The apparatus of claim 1, wherein the processor predicts the dissolution profile of the active agent over a desired dissolution time period, prior to the expiration of the desired dissolution time period and after at least 50 percent of the desired dissolution time period has elapsed.

5. The apparatus of claim 1, wherein the processor predicts a 24 hour dissolution profile of the active agent after 16 hours of dissolution time has elapsed.

6. The apparatus of claim 1, further comprising a display device coupled to the processor, the processor displaying the dissolution profile of the active agent on the display device as a percentage of active agent released versus time.

7. The apparatus of claim 1, wherein, prior to a release of a maximum releasable quantity of the active agent from the dosage form, the processor predicts a dissolution profile of the active agent from zero to the maximum releasable quantity.

8. The apparatus of claim 1, wherein the vessel contains an agitation device.

9. The apparatus of claim 8, wherein the agitation device comprises a paddle attached to a shaft.

10. The apparatus of claim 8, wherein the agitation device comprises a rotating basket attached to a shaft.

11. An apparatus for determining a dissolution profile of a pharmaceutical dosage form containing a releasable quantity of a therapeutically active agent wherein the dosage form is immersed in a dissolution medium contained in a vessel, comprising:

a plurality of vessels for immersing a plurality of pharmaceutical dosage forms in a plurality of dissolution mediums;

a plurality of fiber optic probes, each fiber optic probe disposed within a respective one of the vessels and immersed in the dissolution medium contained in the respective one of the vessels;

a processor coupled to the fiber optic probe, the processor including a computer coupled to a plurality of UV spectrometers, each fiber optic probe being coupled to a respective one of the TV spectrometers, the processor continuously receiving information from each fiber optic probe as the dissolution of each dosage form in its respective dissolution medium proceeds, the processor analyzing the information and continuously generating a dissolution profile of each dosage form as the dissolution of the dosage form in its respective dissolution medium proceeds.

12. A method for determining a dissolution profile of a pharmaceutical dosage form containing a releasable quantity of a therapeutically active agent wherein the dosage form is immersed in a dissolution medium contained in a vessel, comprising the steps of:

immersing a pharmaceutical dosage form in a dissolution medium, the dosage form and the dissolution medium being contained within a vessel;

continuously receiving information from a fiber optic probe as dissolution of the dosage form in the dissolution medium proceeds, said fiber optic probe disposed within the vessel and immersed in the dissolution media as dissolution of the dosage form in the dissolution medium proceeds; and

analyzing the information and continuously generating a dissolution profile of the dosage form as the dissolution of the dosage form in the dissolution medium proceeds.

13. The method of claim 12, further comprising the step of displaying the dissolution profile of the active agent on a display device as a percentage of active agent released versus time.

14. The method of claim 13, further comprising the step of predicting a dissolution profile of the active agent over a desired dissolution time period, prior to the expiration of the desired dissolution time period and after at least 50 percent of the desired dissolution time period has elapsed.

15. The method of claim 12, further comprising the step of predicting a 24 hour dissolution profile of the active agent after 16 hours of dissolution time has elapsed.

16. The method of claim 12, further comprising the step of, prior to a release of a maximum releasable quantity of the active agent from the dosage form, predicting a dissolution profile of the active agent from zero to the maximum releasable quantity.

17. The method of claim 12, wherein generating a dissolution profile of a pharmaceutical dosage form comprises displaying the dissolution profile as a graph of percentage active agent released versus time.

18. The of claim 12, wherein generating a dissolution profile of a pharmaceutical dosage form comprises displaying the dissolution profile as a table of percentage active agent released versus time.